Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$25.42 USD
+0.06 (0.24%)
Updated May 13, 2024 04:00 PM ET
After-Market: $25.44 +0.02 (0.08%) 6:52 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
DCPH 25.42 +0.06(0.24%)
Will DCPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DCPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DCPH
Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
DCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Other News for DCPH
Deciphera Pharmaceuticals: A Hold Rating Amidst Ono Pharmaceutical Acquisition Offer
DCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
Deciphera just downgraded at Stifel, here's why
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Butterfly Network (BFLY) and Deciphera Pharmaceuticals (DCPH)
Wall Street Breakfast: The Week Ahead